Senior Director, DMPK
Cogent Biosciences
Summary
The Senior Director, DMPK is responsible for providing scientific and strategic leadership for Drug Metabolism and Pharmacokinetics activities across Cogent's discovery and development portfolio. This individual will lead the DMPK function and develop and execute DMPK strategies that support small molecule programs from early discovery through candidate selection, IND-enabling studies, and clinical development. The successful candidate will bring deep expertise in ADME, pharmacokinetics, bioanalysis, and translational DMPK and will work closely with Medicinal Chemistry, Biology, Pharmacology, Toxicology, Clinical Pharmacology, and other cross-functional partners. This role will lead an internal DMPK team and oversee external CROs and partners to ensure high-quality data and timely execution of program objectives.
Job description
The Role
The Senior Director, DMPK is responsible for providing scientific and strategic leadership for Drug Metabolism and Pharmacokinetics activities across Cogent's discovery and development portfolio. This individual will lead the DMPK function and develop and execute DMPK strategies that support small molecule programs from early discovery through candidate selection, IND-enabling studies, and clinical development. The successful candidate will bring deep expertise in ADME, pharmacokinetics, bioanalysis, and translational DMPK and will work closely with Medicinal Chemistry, Biology, Pharmacology, Toxicology, Clinical Pharmacology, and other cross-functional partners. This role will lead an internal DMPK team and oversee external CROs and partners to ensure high-quality data and timely execution of program objectives.
Responsibilities
- Lead the DMPK function and provide scientific direction across discovery and development programs.
- Develop and execute integrated DMPK strategies to advance small molecule therapeutics from discovery through clinical development.
- Provide DMPK leadership on project teams and influence compound design, optimization, candidate selection, and development decisions.
- Lead the design and interpretation of in vitro ADME, in vivo PK, PK/PD, and related studies.
- Apply PK modeling and human dose prediction to support candidate selection and clinical development planning.
- Partner closely with Medicinal Chemistry, Biology, Pharmacology, and Toxicology to integrate DMPK data into program strategy.
- Support Clinical and Clinical Pharmacology planning and strategy.
- Oversee bioanalytical strategies supporting PK, PK/PD, toxicokinetic, and other nonclinical studies.
- Provide scientific oversight of metabolite identification, drug-drug interaction, transporter, enzyme kinetics, and other ADME activities.
- Lead DMPK activities supporting IND-enabling programs, regulatory submissions, and responses to health authority questions.
- Manage and develop DMPK scientists, providing scientific guidance, mentorship, and technical leadership.
- Oversee CROs and external partners supporting DMPK and bioanalytical activities, including study design, timelines, data quality, and deliverables.
- Identify emerging technologies and approaches that improve DMPK capabilities and program decision-making.
- Manage functional priorities, resources, budgets, and external spend across multiple programs.
- Communicate DMPK strategy, results, risks, and recommendations to project teams and Research leadership.
Qualifications
- Ph.D. in Drug Metabolism, Pharmaceutical Sciences, Pharmacokinetics, Pharmacology, Chemistry, Biochemistry, or a related scientific discipline.
- 20+ years of pharmaceutical or biotechnology industry experience in DMPK supporting small molecule drug discovery and development.
- Demonstrated experience leading DMPK strategy across multiple programs from discovery through candidate selection and IND-enabling development.
- Experience advancing compounds into clinical development.
- Deep expertise in ADME, pharmacokinetics, drug metabolism, transporters, enzyme kinetics, and PK/PD relationships.
- Strong understanding of in vitro ADME and in vivo PK study design and interpretation.
- Experience with PK modeling, exposure-response relationships, human PK and dose prediction, and translation of nonclinical data to the clinic.
- Strong understanding of quantitative bioanalysis and LC-MS/MS techniques.
- Experience supporting INDs and other regulatory submissions, including preparation and review of DMPK-related regulatory documents.
- Demonstrated experience leading and developing scientists and providing technical direction across a DMPK function.
- Experience managing CROs and other external scientific partners.
- Strong understanding of the integrated drug discovery process and the relationship between DMPK, Medicinal Chemistry, Biology, Pharmacology, Toxicology, and clinical development.
- Demonstrated ability to work across multiple programs, establish priorities, and make timely, data-driven recommendations.
- Strong scientific judgment, critical thinking, and problem-solving skills.
- Excellent written and verbal communication skills, with the ability to clearly communicate complex DMPK data and recommendations to scientific and leadership audiences.
Requirements
- Ph.D. in Drug Metabolism, Pharmaceutical Sciences, Pharmacokinetics, Pharmacology, Chemistry, Biochemistry, or a related scientific discipline
- 20+ years of pharmaceutical or biotechnology industry experience in DMPK supporting small molecule drug discovery and development
- Demonstrated experience leading DMPK strategy across multiple programs from discovery through candidate selection and IND-enabling development
- Experience advancing compounds into clinical development
- Deep expertise in ADME, pharmacokinetics, drug metabolism, transporters, enzyme kinetics, and PK/PD relationships
- Strong understanding of in vitro ADME and in vivo PK study design and interpretation
- Experience with PK modeling, exposure-response relationships, human PK and dose prediction, and translation of nonclinical data to the clinic
- Strong understanding of quantitative bioanalysis and LC-MS/MS techniques
- Experience supporting INDs and other regulatory submissions, including preparation and review of DMPK-related regulatory documents
- Demonstrated experience leading and developing scientists and providing technical direction across a DMPK function
- Experience managing CROs and other external scientific partners
- Strong understanding of the integrated drug discovery process and the relationship between DMPK, Medicinal Chemistry, Biology, Pharmacology, Toxicology, and clinical development
- Demonstrated ability to work across multiple programs, establish priorities, and make timely, data-driven recommendations
- Strong scientific judgment, critical thinking, and problem-solving skills
- Excellent written and verbal communication skills
Benefits
- Medical, Dental & Vision
- 401(k) Matching
- Paid Time Off
- Paid Parental Leave
- Paid Family & Medical Leave
- Short-Term Disability
- Wellness Programs
- Tuition Reimbursement
- Stock Awards
- Target Bonus 25%
Company overview
Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat patients with genetically defined diseases. Founded in 2014 and headquartered in Waltham, Massachusetts with research operations in Boulder, Colorado, the company leverages validated biology to address the true underlying drivers of disease. Cogent's lead program, bezuclastinib, is designed to selectively inhibit exon 17 mutations within the KIT receptor tyrosine kinase, targeting conditions such as Systemic Mastocytosis and gastrointestinal stromal tumors (GIST). The company has demonstrated promising clinical activity in Phase 1/2 trials and is advancing multiple late-stage clinical programs. With a world-class discovery organization and a focus on rational precision therapy design, Cogent aims to create best-in-class small molecule therapeutics that improve upon existing treatments with limitations and safety concerns. The company employs 51-200 professionals and has raised significant funding, including a recent $230 million post-IPO equity round, positioning it as an emerging leader in precision oncology and rare disease therapeutics.